Most children allergic to multiple foods have achieved success in long-term regular consumption of these foods in their diet. Success was similar in children treated with oral immunotherapy (OIT) and those receiving omalizumab (Xolair) alone. The results come from the 3rd phase of the OUtMATCH study. The study was conducted in Philadelphia and published by MedPage Today. The treatment made it possible to transform foods forbidden for allergy sufferers into normal foods. The biologic drug omalizumab was shown to be on par with OIT.